{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Efavirenz+600mg&page=2", "query": { "intervention": "Efavirenz 600mg", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 27, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Efavirenz+600mg&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Efavirenz+600mg&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-07T14:56:47.423Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00862823", "title": "The Bioequivalence of Atripla in an Oral Liquid Formulation Compared With the Tablet Formulation in Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "tenofovir, emtricitabine and efavirenz fixed dose tablet", "type": "DRUG" }, { "name": "tenofovir, emtricitabine and efavirenz tablet added to solution", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "19 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "19 Years to 65 Years" }, "enrollment_count": 14, "start_date": "2009-02", "completion_date": "2010-05", "has_results": true, "last_update_posted_date": "2012-09-14", "last_synced_at": "2026-10-07T14:56:47.423Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT00862823" }, { "nct_id": "NCT00004585", "title": "A Study of the Safety and Effectiveness of Combination Anti-HIV Therapy in HIV-Infected Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Abacavir sulfate, Lamivudine and Zidovudine", "type": "DRUG" }, { "name": "Lamivudine/Zidovudine", "type": "DRUG" }, { "name": "Abacavir sulfate", "type": "DRUG" }, { "name": "Efavirenz", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Glaxo Wellcome", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "1999-10", "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-10-07T14:56:47.423Z", "location_count": 5, "location_summary": "Los Angeles, California • Washington D.C., District of Columbia • Manhasset, New York + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Manhasset", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004585" }, { "nct_id": "NCT01098526", "title": "GSK1349572 Drug Interaction Study With Efavirenz", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Infections, Human Immunodeficiency Virus and Herpesviridae" ], "interventions": [ { "name": "GSK1349572", "type": "DRUG" }, { "name": "Efavirenz", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 12, "start_date": "2010-03-16", "completion_date": "2010-05-26", "has_results": false, "last_update_posted_date": "2017-09-25", "last_synced_at": "2026-10-07T14:56:47.423Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01098526" }, { "nct_id": "NCT00042289", "title": "Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "atazanavir/cobicistat", "type": "DRUG" }, { "name": "darunavir/ritonavir dosage #1", "type": "DRUG" }, { "name": "darunavir/ritonavir dosage #2", "type": "DRUG" }, { "name": "darunavir/ritonavir dosage #3", "type": "DRUG" }, { "name": "elvitegravir/cobicistat", "type": "DRUG" }, { "name": "dolutegravir", "type": "DRUG" }, { "name": "tenofovir alafenamide fumarate (TAF)", "type": "DRUG" }, { "name": "TAF w/cobicistat", "type": "DRUG" }, { "name": "TAF w/cobicistat or ritonavir", "type": "DRUG" }, { "name": "efavirenz", "type": "DRUG" }, { "name": "darunavir/cobicistat", "type": "DRUG" }, { "name": "lopinavir/ritonavir dosage #1", "type": "DRUG" }, { "name": "atazanavir/ritonavir/tenofovir dosage #1", "type": "DRUG" }, { "name": "rifampicin", "type": "DRUG" }, { "name": "ethambutol", "type": "DRUG" }, { "name": "isoniazid", "type": "DRUG" }, { "name": "pyrazinamide", "type": "DRUG" }, { "name": "kanamycin", "type": "DRUG" }, { "name": "amikacin", "type": "DRUG" }, { "name": "capreomycin", "type": "DRUG" }, { "name": "moxifloxacin", "type": "DRUG" }, { "name": "levoflaxacin", "type": "DRUG" }, { "name": "ofloxacin", "type": "DRUG" }, { "name": "ethionamide/prothionamide", "type": "DRUG" }, { "name": "terizidone/cycloserine", "type": "DRUG" }, { "name": "para-aminosalicylic acid (PAS)", "type": "DRUG" }, { "name": "high dose INH", "type": "DRUG" }, { "name": "bedaquiline", "type": "DRUG" }, { "name": "clofazamine", "type": "DRUG" }, { "name": "delamanid", "type": "DRUG" }, { "name": "linezolid", "type": "DRUG" }, { "name": "pretomanid", "type": "DRUG" }, { "name": "ethinyl estradiol", "type": "DRUG" }, { "name": "etonogestrel implant", "type": "DRUG" }, { "name": "nevirapine", "type": "DRUG" }, { "name": "amprenavir", "type": "DRUG" }, { "name": "abacavir", "type": "DRUG" }, { "name": "lopinavir/ritonavir dosage #2", "type": "DRUG" }, { "name": "indinavir/ritonavir dosage #1", "type": "DRUG" }, { "name": "fosamprenavir/ritonavir", "type": "DRUG" }, { "name": "lopinavir/ritonavir dosage #3", "type": "DRUG" }, { "name": "atazanavir/ritonavir dosage #1", "type": "DRUG" }, { "name": "didanosine delayed release (Videx® EC)", "type": "DRUG" }, { "name": "emtricitabine", "type": "DRUG" }, { "name": "tenofovir", "type": "DRUG" }, { "name": "nelfinavir dosage #1", "type": "DRUG" }, { "name": "tipranavir/ritonavir", "type": "DRUG" }, { "name": "lopinavir/ritonavir dosage #4", "type": "DRUG" }, { "name": "raltegravir", "type": "DRUG" }, { "name": "etravirine", "type": "DRUG" }, { "name": "maraviroc", "type": "DRUG" }, { "name": "atazanavir/ritonavir dosage #2", "type": "DRUG" }, { "name": "tenofovir/atazanavir/ritonavir dosage #2", "type": "DRUG" }, { "name": "nelfinavir dosage #2", "type": "DRUG" }, { "name": "indinavir/ritonavir dosage #2", "type": "DRUG" }, { "name": "rilpivirine", "type": "DRUG" }, { "name": "darunavir/ritonavir dosage #4", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 1578, "start_date": "2003-06-09", "completion_date": "2020-09-30", "has_results": true, "last_update_posted_date": "2025-12-02", "last_synced_at": "2026-10-07T14:56:47.423Z", "location_count": 39, "location_summary": "Birmingham, Alabama • La Jolla, California • Long Beach, California + 26 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00042289" }, { "nct_id": "NCT02415595", "title": "Dose-finding Study of BMS-955176 to Treat HIV-1 Infected Treatment-naive Adults", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Infection, Human Immunodeficiency Virus" ], "interventions": [ { "name": "BMS-955176", "type": "DRUG" }, { "name": "EFV", "type": "DRUG" }, { "name": "TDF/FTC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 210, "start_date": "2015-05-12", "completion_date": "2017-08-21", "has_results": true, "last_update_posted_date": "2018-09-19", "last_synced_at": "2026-10-07T14:56:47.423Z", "location_count": 8, "location_summary": "Beverly Hills, California • Los Angeles, California • DeLand, Florida + 5 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "DeLand", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Decatur", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02415595" }, { "nct_id": "NCT02401256", "title": "CYP2B6 Genetics and Drug Interactions in Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Efavirenz", "type": "DRUG" }, { "name": "Bupropion", "type": "DRUG" }, { "name": "Rosuvastatin", "type": "DRUG" }, { "name": "Montelukast", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Indiana University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "49 Years", "sex": "ALL", "summary": "18 Years to 49 Years" }, "enrollment_count": 70, "start_date": "2013-07", "completion_date": "2016-05-31", "has_results": true, "last_update_posted_date": "2017-10-11", "last_synced_at": "2026-10-07T14:56:47.423Z", "location_count": 1, "location_summary": "Indianapolis, Indiana", "locations": [ { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT02401256" }, { "nct_id": "NCT00266058", "title": "Drug Interaction Study Between Antimalarial and Anti-HIV Medications", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections", "Malaria" ], "interventions": [ { "name": "Lopinavir/Ritonavir, Efavirenz, Artemether/lumefantrine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "21 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "21 Years to 60 Years" }, "enrollment_count": 33, "start_date": "2005-12", "completion_date": "2010-11", "has_results": false, "last_update_posted_date": "2013-06-06", "last_synced_at": "2026-10-07T14:56:47.423Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00266058" }, { "nct_id": "NCT00661960", "title": "Pilot Project of Virologic and Immunologic Correlates of GALT Immune Reconstitution Following Raltegravir Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HIV Infections", "AIDS" ], "interventions": [ { "name": "raltegravir", "type": "DRUG" }, { "name": "efavirenz", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, Davis", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 25, "start_date": "2008-03", "completion_date": "2011-07", "has_results": true, "last_update_posted_date": "2017-05-30", "last_synced_at": "2026-10-07T14:56:47.423Z", "location_count": 2, "location_summary": "Sacramento, California", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00661960" }, { "nct_id": "NCT01867996", "title": "A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Retosiban (GSK221149) When Dosed With Efavirenz (EFZ)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Obstetric Labour, Premature" ], "interventions": [ { "name": "Retosiban", "type": "DRUG" }, { "name": "EFZ 600 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 18, "start_date": "2013-06-11", "completion_date": "2013-09-26", "has_results": false, "last_update_posted_date": "2017-05-11", "last_synced_at": "2026-10-07T14:56:47.423Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01867996" }, { "nct_id": "NCT00005018", "title": "Safety and Effectiveness of a Combination Anti-HIV Drug Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Hydroxyurea", "type": "DRUG" }, { "name": "Abacavir sulfate", "type": "DRUG" }, { "name": "Efavirenz", "type": "DRUG" }, { "name": "Didanosine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Glaxo Wellcome", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": null, "sex": "ALL", "summary": "13 Years and older" }, "enrollment_count": 150, "start_date": "1999-07", "completion_date": "2000-10", "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-10-07T14:56:47.423Z", "location_count": 23, "location_summary": "Berkeley, California • Beverly Hills, California • Los Angeles, California + 19 more", "locations": [ { "city": "Berkeley", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005018" } ] }